[Tocilizumab therapy for immune checkpoint inhibitor associated myocarditis: a case report]

S J Wu; X H Liu; W Wu; M Qian; L Li; L Zhang; H H Yang; M Guan; J Cao; Y N Wang; G R Ruan; N Niu; Y X Liu

doi:10.3760/cma.j.cn112148-20210511-00412

[Tocilizumab therapy for immune checkpoint inhibitor associated myocarditis: a case report]

Zhonghua Xin Xue Guan Bing Za Zhi. 2022 Apr 24;50(4):397-400. doi: 10.3760/cma.j.cn112148-20210511-00412.

[Article in Chinese]

Authors

S J Wu¹, X H Liu¹, W Wu², M Qian³, L Li², L Zhang⁴, H H Yang⁵, M Guan⁶, J Cao⁷, Y N Wang⁷, G R Ruan⁸, N Niu⁹, Y X Liu²

Affiliations

¹ Department of Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.
² Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.
³ Department of Neurology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.
⁴ Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.
⁵ Department of Rheumatology and Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.
⁶ Department of Oncology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.
⁷ Department of Radiology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.
⁸ Department of Infectious Disease, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.
⁹ Department of Nuclear Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.

PMID: 35399037
DOI: 10.3760/cma.j.cn112148-20210511-00412

Abstract

随着肿瘤免疫治疗的推广，免疫检查点抑制剂（ICI）相关不良反应（irAE）日益受到关注。该文报道了1例ICI相关心肌炎、肌炎患者，对激素治疗反应不佳，合并菌血症，在托珠单抗、丙种球蛋白及充分抗生素治疗后，全身炎症状态得到控制，心功能好转。该文结合临床诊疗经验和文献，探讨了ICI相关心肌炎的发病机制、诊断思路及治疗策略，以期加深临床医师对此类疾病的认识。.

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Humans
Immune Checkpoint Inhibitors / adverse effects
Myocarditis* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
Immune Checkpoint Inhibitors
tocilizumab